DrugPatentWatch Database Preview
Drugs in Development Information for DEBIO-1347
» See Plans and Pricing
What is the drug development status for DEBIO-1347?
DEBIO-1347 is an investigational drug.
There have been 21 clinical trials for DEBIO-1347.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 15th 2020.
The most common disease conditions in clinical trials are Bacterial Infections, Infection, and Hepatitis C. The leading clinical trial sponsors are Debiopharm International SA, Parexel, and GORTEC (Head and Neck Oncology and Radiotherapy Group).
There are five US patents protecting this investigational drug and eighty-two international patents.
Summary for DEBIO-1347
| US Patents | 5 |
| International Patents | 82 |
| US Patent Applications | 13 |
| WIPO Patent Applications | 7 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 2 (2020-07-15) |
| Vendors | 39 |
Recent Clinical Trials for DEBIO-1347
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiot | GORTEC (Head and Neck Oncology and Radiotherapy Group) | Phase 3 |
| A Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiot | Debiopharm International SA | Phase 3 |
| Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors | Debiopharm International SA | Phase 1 |
Clinical Trial Summary for DEBIO-1347
Top disease conditions for DEBIO-1347
Top clinical trial sponsors for DEBIO-1347
US Patents for DEBIO-1347
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| DEBIO-1347 | Start Trial | FGFR gatekeeper mutant gene and drug targeting same | Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) | Start Trial |
| DEBIO-1347 | Start Trial | FGFR3 fusion gene and pharmaceutical drug targeting same | Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) | Start Trial |
| DEBIO-1347 | Start Trial | Aminopyrazole derivative | Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) F. Hoffmann-La Roche AG (Basel, CH) | Start Trial |
| DEBIO-1347 | Start Trial | Aminopyrazole derivative | Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) F. Hoffmann-La Roche AG (Basel, CH) | Start Trial |
| DEBIO-1347 | Start Trial | Pharmaceutical preparation comprising aminopyrazole derivative | Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for DEBIO-1347
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| DEBIO-1347 | Denmark | DK3087986 | 2033-12-27 | Start Trial |
| DEBIO-1347 | European Patent Office | EP3087986 | 2033-12-27 | Start Trial |
| DEBIO-1347 | European Patent Office | EP3581179 | 2033-12-27 | Start Trial |
| DEBIO-1347 | Spain | ES2756175 | 2033-12-27 | Start Trial |
| DEBIO-1347 | Japan | JP6514645 | 2033-12-27 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
